Financial Data and Key Metrics Changes - In 2025, total revenue reached RMB 2.37 billion, representing a 135% year-over-year growth [4][15] - Product sales amounted to RMB 1.44 billion, up 43% from the previous year [4][15] - The company achieved a net profit of RMB 644 million, marking its first profitable year [4][15] - Cash position at the end of 2025 was RMB 2.8 billion, supporting ongoing R&D investments [5][16] - R&D expenses were RMB 950 million, reflecting a 16.9% year-over-year growth [16] Business Line Data and Key Metrics Changes - Orelabrutinib received regulatory approval for multiple indications, significantly expanding its commercial space [10][11] - Tafasitamab was approved for DLBCL in mainland China, enhancing the company's oncology portfolio [10][20] - Mesutoclax is being developed for four indications, with ongoing clinical trials showing promising results [11][25] Market Data and Key Metrics Changes - The global partnership strategy yielded a total business development deal value exceeding $2.5 billion in 2025 [5][18] - The company is focusing on expanding its presence in both domestic and international markets, with significant breakthroughs in globalization [18][19] Company Strategy and Development Direction - The company aims to become a global pharmaceutical leader by focusing on oncology and autoimmune diseases [4] - A diversified product portfolio is being developed, transitioning into multiple commercial and late-stage assets [15][17] - The company is investing in innovative platforms such as ADC and molecular glue technologies to enhance its R&D capabilities [16][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over 35% growth in drug sales for 2026, driven by Orelabrutinib and new product launches [17][54] - The company anticipates continued profitability and sustainable growth, supported by a strong pipeline and business development opportunities [55][62] Other Important Information - The company has over 10 phase III registrational studies ongoing, with multiple major products expected to receive regulatory approvals in the next two to three years [14][19] - The first ADC product, ICP-B794, is in the dose escalation stage of phase I trials, showing promising preliminary results [40][46] Q&A Session Summary Question: What is the sales potential for Orelabrutinib in 2026? - Management expects Orelabrutinib to continue growing over 30% due to deeper penetration in CLL and MCL, along with broader hospital coverage [51][53] Question: What is the development plan for ICP-488 overseas? - The company plans to expand indications after the phase III readout and is open to partnerships for global development [57][59] Question: What is the forecast for R&D expenses in 2026? - R&D expenses are expected to grow by around 20% in 2026, focusing on late-stage clinical studies and innovation platforms [61][62] Question: How will ICP-488 position itself against competitors in the psoriasis market? - The company believes its TYK2 inhibitor has a broader potential compared to oral IL-23 therapies, targeting multiple autoimmune diseases [73][75] Question: What are the inclusion criteria for the Orelabrutinib plus Mesutoclax data? - The combination therapy shows promising results in unfit older patients, providing a good treatment option for this population [78]

Financial Data and Key Metrics Changes - In 2025, total revenue reached RMB 2.37 billion, representing a 135% year-over-year growth [4][15] - Product sales reached RMB 1.44 billion, up 43% over the previous year [4][15] - Net profit reached RMB 644 million, marking the company's first year with a profit [4][17] - Cash position at the end of 2025 was RMB 2.8 billion, supporting continued R&D investment [5][17] - R&D expenses were RMB 950 million, reflecting a 16.9% year-over-year growth [17][61] Business Line Data and Key Metrics Changes - Orelabrutinib was approved for first-line treatment of CLL/SLL and included in NRDL, expanding commercial space [5][11] - Tafasitamab was approved for DLBCL in mainland China, enhancing the company's oncology portfolio [5][11] - Zurletrectinib was approved for marketing in China, marking the company's first approved therapy in solid tumors [11][40] Market Data and Key Metrics Changes - The company entered into strategic collaborations with Zenas BioPharma and Freelium, unlocking significant value with total BD deal value exceeding $2.5 billion [5][19] - Globalization is becoming a key growth pillar, with major out-license transactions covering four assets [19] Company Strategy and Development Direction - The company aims to become a global pharmaceutical leader focused on innovative therapies for oncology and autoimmune diseases [4] - A diversified product portfolio is being developed, with multiple commercial and late-stage assets driving future expansion [15][18] - The company is investing in next-generation platforms such as ADC and molecular glue technologies [17][61] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over 35% growth in drug sales for 2026, driven by Orelabrutinib, Tafasitamab, and Zurletrectinib [18][54] - The company achieved profitability ahead of schedule, with expectations for sustainable breakeven in 2026 and 2027 [54][56] Other Important Information - The company has over 10 phase III registrational studies ongoing globally, with multiple major products expected to receive regulatory approvals in the next 2-3 years [14][20] - The pipeline includes innovative therapies for autoimmune diseases, with significant market potential exceeding $150 billion [36][29] Q&A Session Summary Question: What is the sales potential for Orelabrutinib in 2026? - Management expects continued growth over 30% for Orelabrutinib, driven by deeper penetration in CLL and MCL, and broader hospital coverage [52][53] Question: What is the development plan for ICP-488 overseas? - The company plans to expand indications after the phase III readout and is open to partnerships for global development [57][59] Question: What is the forecast for R&D expenses in 2026? - R&D expenses are expected to grow around 20% in 2026, focusing on late-stage clinical studies and innovation platforms [61][62] Question: How will the company position its TYK2 inhibitors amid competition? - The company believes its TYK2 inhibitors have broader potential beyond psoriasis, targeting multiple autoimmune diseases [72][73] Question: What are the inclusion criteria for the Orelabrutinib plus Mesutoclax data? - The combination therapy targets unfit older patients, achieving a 65% MRD-negative rate, demonstrating good results in this population [79]

Core Insights - InnoCare Pharma achieved its first full year of profitability in 2025, marking a significant milestone in its 10th anniversary, with revenue growth driven by strategic business development and enhanced market penetration of core products [2][9] - The company secured two new drug application approvals and accelerated its globalization strategy through transformative licensing agreements, enhancing its global influence and financial performance [4][5] Financial Highlights - Revenue grew 135.3% year-on-year to RMB 2,375 million in 2025, primarily due to robust commercial growth and strategic business development deals [9] - Profit reached RMB 644 million, achieving profitability for the first time, attributed to significant commercialization growth and global out-licensing deals [9] - Gross Profit Margin increased by 5.7 percentage points to 92% [9] - Research and Development Investment rose by 16.9% to RMB 952 million, reflecting advancements in multiple Phase III trials and increased investments in new technology platforms [9] - Cash and Related Accounts Balance stood at approximately RMB 7.8 billion as of December 31, 2025, with positive operating cash flow for the first time [9] Globalization Strategy - InnoCare accelerated its globalization strategy in 2025, unlocking global value through two out-licensing deals, significantly enhancing its global presence [4][5] - A licensing agreement with Zenas for its autoimmune disease pipeline, including orelabrutinib, has a total deal value exceeding US$2 billion, setting a record for small molecule autoimmune out-licensing in China [5][6] - Another licensing agreement with Prolium aims to further expand InnoCare's global presence, with ongoing clinical studies expected to advance in 2026 [7] Hemato-Oncology Franchise - InnoCare made significant progress in building a leading hemato-oncology franchise, with orelabrutinib approved for first-line chronic lymphocytic leukemia/small lymphocytic lymphoma and tafasitamab becoming the first CD19 antibody approved for relapsed or refractory diffuse large B-cell lymphoma in China [11][16] - Drug sales in this segment increased by 43.4% to RMB 1,442 million in 2025 [11] - Mesutoclax (ICP-248), the first BCL2 inhibitor granted Breakthrough Therapy Designation in China, continues to advance across multiple indications, supporting near-term revenue growth [12][19] Autoimmune Disease Pipeline - The global market for autoimmune disease therapeutics is projected to reach $185 billion by 2029, with InnoCare focusing on B-cell and T-cell pathways to develop first-in-class treatments [22] - Orelabrutinib is positioned to address significant unmet medical needs in immune thrombocytopenia and systemic lupus erythematosus, with pivotal studies showing promising results [23][24] - The company is collaborating with Zenas to accelerate global Phase III clinical trials for orelabrutinib in multiple sclerosis, tapping into a market exceeding US$12 billion [25] Solid Tumor Development - InnoCare is building a diversified portfolio for solid tumors, combining targeted small molecules with next-generation antibody-drug conjugates (ADCs) [39] - Zurletrectinib (ICP-723), a next-generation TRK inhibitor, has shown outstanding efficacy in clinical trials for NTRK gene fusion-positive tumors, with an overall response rate of 89.1% [40][41] - The company is advancing multiple ADC candidates, including ICP-B794 and ICP-B208, targeting solid tumors with promising preclinical results [45][47]

InnoCare Pharma (9969.HK) Earnings Review Summary Company Overview - **Company**: InnoCare Pharma (9969.HK) - **Industry**: Biotechnology Key Financial Highlights - **3Q Orela Sales**: Rmb383 million, representing a **39% year-over-year (y/y)** increase and **18% quarter-over-quarter (q/q)** growth, compared to **4% q/q** in 2Q25 [1] - **Net Loss**: Reduced to **-Rmb34 million** from **-Rmb48 million** in 2Q25, with slower growth in Selling, General and Administrative (SG&A) expenses at **19% y/y** [1] - **2025 Guidance**: Management raised orela sales growth guidance to **40% y/y** from the previous **35% y/y** [1] Growth Drivers - **Hospital Coverage**: Expansion in low-tier markets contributed to sales growth [1] - **MZL Growth**: Solid growth in MZL accounted for approximately **40%** of new patient acquisitions [1] - **Future Sales Momentum**: Expected continued growth in orela sales in 2026E at **28% y/y**, driven by newly reimbursed 1L CLL/SLL indication [1] New Product Development - **Tafasitamab**: Targeting the self-pay market with expected sales of **Rmb100 million to Rmb200 million** in 2026 [1] - **Immunology Pipeline**: Ongoing development with multiple catalysts: - **ICP-332**: Phase 3 data on AD expected by week 16 and phase 2 data for vitiligo in mid-2026 [3] - **ICP-488**: Phase 3 trial for psoriasis aiming for patient enrollment completion by year-end 2025 [3] - **Orelabrutinib**: Phase 2b data for SLE to be released in 4Q25 [3] Profitability Outlook - **Profitability Expectations**: Management anticipates turning profitable in 2025 post-Zenas deal, with core business profits expected by 2027 [2] - **R&D Expenses**: Projected at nearly **Rmb1 billion** for 2025, with a **15% y/y** growth expected for 2026 [2] - **Selling Expenses**: Anticipated growth of **35%-40% y/y** in 2026 to support the commercial launch of ITP indication in 2027 [2] Price Target and Risks - **12-Month Price Target**: Revised to **HK$24.54** for H-Share and **Rmb47.28** for A-Share, reflecting an **upside of 61.8%** and **86.6%** respectively [9][11] - **Key Risks**: Include R&D risks for clinical assets, uncertainties in pricing, potential entry of generic ibrutinib in 2027, and below-expected progress in global expansion [10] Conclusion - InnoCare Pharma shows strong sales growth and a promising pipeline, with management optimistic about future profitability and market expansion. The raised guidance and ongoing clinical trials position the company favorably within the biotechnology sector.

Group 1 - The core viewpoint of the report is that Nuo Cheng Jian Hua (688428.SH) is given a "buy" rating due to several positive developments in its product pipeline and market approvals [1] - The approval of Obinutuzumab for 1LCLL/SLL indications in China is expected to drive rapid market growth [1] - Tafasitamab has received NMPA approval, indicating potential for commercial growth [1] - The company has initiated two registration clinical studies for ICP-248, indicating a global acceleration in its development strategy [1] - Nuo Cheng Jian Hua continues to explore multiple indications in the autoimmune field, with several innovative oral therapies progressing in development [1] - The company has submitted an NDA for ICP-732 in China and received priority review, while its first ADC candidate, ICP-B794, has been granted IND approval domestically [1] Group 2 - The A-share market has seen trading volumes exceed 2 trillion yuan for eight consecutive days, indicating strong market activity [2] - Major brokerage firms are actively recruiting for autumn positions, highlighting a demand for talent in the industry [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved strong revenue growth in H1 2025, with a revenue of 731 million yuan, representing a year-on-year increase of 74.26%. The core product, Aobutini, saw a sales revenue of approximately 641 million yuan, up 53.5% year-on-year [6] - The company is focusing on building a product matrix in the hematology field centered around Aobutini, with promising early data for its BCL-2 inhibitor ICP-248 [6] - There is optimism regarding Aobutini's potential in international markets, particularly in the autoimmune sector, with ongoing clinical trials for multiple indications [7] Financial Summary - Revenue projections for 2025-2027 are 1.47 billion yuan, 1.79 billion yuan, and 2.21 billion yuan, reflecting year-on-year growth rates of 45.7%, 21.7%, and 23.3% respectively [6] - The company is expected to maintain a gross margin of around 87.3% in 2025, with a net margin projected to improve to -23.2% [9][12] - The company's total market capitalization is approximately 53.59 billion yuan, with a current stock price of 30.37 yuan [1]

Group 1 - The company reported a revenue of 731 million yuan in the first half of 2025, a 74.76% increase compared to 420 million yuan in the same period last year [1] - Pharmaceutical sales revenue reached 641 million yuan, up 53.47% from 418 million yuan year-on-year [1] - The company achieved a net profit attributable to shareholders of -30 million yuan, narrowing the loss by 88.51% compared to -262 million yuan in the same period last year [1] Group 2 - The flagship product, Obinutuzumab, generated sales of 637 million yuan in the first half of 2025, reflecting a year-on-year growth of 52.84% [1] - The company received breakthrough therapy designation for ICP-248, which targets MCL (after BTK inhibitor treatment failure), with plans for clinical trials in four indications [1] - The first domestic CD19 monoclonal antibody, Tafasitamab, has been approved for use in combination with Lenalidomide for r/r DLBCL, with sales expected to start between late Q3 and early Q4 [1] Group 3 - Obinutuzumab's international phase III clinical trial for SPMS and PPMS has received FDA approval, with subject recruitment expected to begin in the second half of 2025 [2] - The company is exploring international collaboration potential for ICP-332 and ICP-488, two TYK2 inhibitors, across multiple indications [2] - Revenue projections for the company are estimated at 1.413 billion yuan, 1.787 billion yuan, and 2.385 billion yuan for 2025, 2026, and 2027 respectively [2]

Company Overview - InnoCare aims to become a global biopharmaceutical leader, focusing on oncology and autoimmune diseases[6, 7, 8] - The company has raised a total of $134 billion USD since its founding in 2015[11] - InnoCare has a fully-integrated drug innovation platform with 13 clinical products in the pipeline and 2 marketed products[13] Orelabrutinib (BTKi) - Orelabrutinib demonstrates ~100% BTK occupation at 50 mg QD and above, with an improved safety profile[23] - Orelabrutinib has shown an 83% overall response rate (ORR) in r/r MCL patients and a 589% ORR in r/r MZL patients[34] - A Phase III registrational trial for Orelabrutinib is ongoing in China for SLE[52] ICP-332 (TYK2 Inhibitor) - ICP-332, at 80mg QD, achieved a 782% reduction from baseline in EASI score in Atopic Dermatitis (AD) patients[75] - 88% of patients achieved EASI 50 and 72% achieved EASI 75 at Week 4 with ICP-332 treatment[75] - Global AD market is expected to reach $222 billion USD by 2028[71] Portfolio Expansion - Tafasitamab BLA submission in China is planned for 2024Q2, targeting 160,000 new DLBCL patients globally per annum[46] - ICP-248 (BCL-2 inhibitor) showed 100% efficacy (6 out of 6 patients) in early clinical results[41] - InnoCare plans to submit an NDA for 1L CLL/SLL in China and r/r MCL in the USA for Orelabrutinib in the second half of 2024[102]

Group 1: Financial Performance - In Q1 2025, the company achieved revenue of 381 million yuan, representing a year-on-year increase of 129.92%, with a net profit attributable to shareholders of 17.97 million yuan and a non-GAAP net profit of 1.59 million yuan [1] - The revenue from Obinutuzumab reached 311 million yuan in Q1 2025, showing an increase of 89.22%, driven by the rapid growth in demand for the exclusive MZL indication [1] Group 2: Product Development and Pipeline - The company is advancing multiple innovative drug developments, with Tafasitamab expected to receive approval in the first half of 2025, enhancing the product pipeline in the hematological oncology field [2] - The global Phase III clinical study for Obinutuzumab in PPMS/SPMS is expected to complete the first patient enrollment within 2025, while the ITP indication is in Phase III and is anticipated to submit an NDA in the first half of 2026 [1][2] - The company has submitted an NDA for the pan-TRK inhibitor zurletrectinib (ICP-723), which has been granted priority review status [2] Group 3: Revenue Forecast and Valuation - The company has adjusted its revenue forecasts, expecting revenues of 1.442 billion yuan, 1.737 billion yuan, and 2.128 billion yuan for 2025 to 2027, with year-on-year growth rates of 42.8%, 20.5%, and 22.5% respectively [3] - The projected net profit attributable to shareholders for the same period is expected to be -259 million yuan, -214 million yuan, and -213 million yuan, leading to corresponding PE ratios of -140.7, -169.7, and -170.8 [3]

Investment Rating - The report assigns a "Buy" rating for the company, marking it as the first coverage [4]. Core Viewpoints - The company is positioned as a leader in the domestic blood cancer drug market, with continuous innovation driving steady growth. It has a strong pipeline of products in development and is expected to expand its commercial offerings significantly in the near future [8][15]. - The company has successfully raised a total of $1.34 billion through multiple funding rounds from 2020 to 2022, which has been directed towards enhancing research and development efforts [8][15]. - The company is expected to achieve revenues of 1.01 billion yuan in 2024, representing a year-on-year growth of 36.8%, with a projected net loss of 444 million yuan, a reduction of approximately 30% compared to the previous year [8][15]. Financial Summary - **Revenue Forecasts**: - 2022: 625 million yuan - 2023: 739 million yuan - 2024E: 1,010 million yuan - 2025E: 1,442 million yuan - 2026E: 1,797 million yuan - **Growth Rates**: - 2023: 18.1% - 2024E: 36.8% - 2025E: 42.7% - 2026E: 24.7% [8][15]. - **Net Profit Forecasts**: - 2022: -887 million yuan - 2023: -631 million yuan - 2024E: -444 million yuan - 2025E: -300 million yuan - 2026E: -214 million yuan [8][15]. - **Return on Equity (ROE)**: - 2022: -11.7% - 2023: -9.0% - 2024E: -6.7% - 2025E: -4.8% - 2026E: -3.5% [8][15]. Product Pipeline - The company has 13 products in development, with two already commercialized. The pipeline includes several products that are expected to enter the market soon, such as ICP-723 and various indications for Obinutuzumab [8][23]. - The company is focusing on blood cancers, autoimmune diseases, and solid tumors, with a significant number of products in late-stage clinical trials [8][23]. Market Position - The company is recognized as the fifth A+H listed pharmaceutical company in China, with a management team that possesses extensive experience in drug development and commercialization [15][19]. - The company has established a strong market presence through its lead product, Obinutuzumab, which has been pivotal in its revenue growth since its launch [8][15].